A significant number of people would get tested for dementia if effective treatments were available, according to Alzheimer’s Disease International (ADI). The organization, which works with dementia associations in over 100 countries, recently conducted a survey involving 40,000 people across 166 nations. The results show a strong willingness among the public to undergo testing, provided there are options for managing the disease.
Professor Hamid Sohrabi, a clinical neuroscientist at Murdoch University in Australia, has developed a new screening tool called the McCusker Subjective Cognitive Impairment Inventory (McSCI-S). This test is designed to identify early signs of dementia by assessing changes in memory, language, concentration, and other cognitive abilities. The questionnaire, which has been translated into several languages, is set to be released for clinical use in China.
The McSCI-S helps doctors determine whether a more comprehensive assessment is needed and whether a patient may be at higher risk for dementia. If a risk is identified, healthcare providers can intervene by addressing modifiable risk factors such as high blood pressure, cholesterol levels, and social connections, or by enrolling patients in clinical trials focused on dementia prevention.
Despite the promise of early detection, Sohrabi advises against using the test independently. He emphasizes that the results should be interpreted by a healthcare professional who can consider other medical information and use clinical judgment to make informed decisions.
Timely diagnosis is crucial for those living with dementia, according to ADI’s CEO Paola Barbarino. Early identification can provide access to support and resources, allowing individuals to live well, stay engaged in their communities, and even continue working. Barbarino attributes the growing public interest in dementia testing to increased awareness of the condition and new treatments that modify disease progression.
Recent advancements in Alzheimer’s treatments include the approval of drugs like donanemab and lecanemab, which aim to slow the disease’s progression. Donanemab, the latest in a series of targeted Alzheimer’s drugs, has shown promising results, reducing cognitive decline by approximately 35% over 18 months. It works by targeting amyloid plaques in the brain, helping to prevent further damage.
However, the availability and cost of these treatments pose significant challenges. While donanemab has been approved in some countries, it is not yet widely accessible. In the UK, for example, it is only available privately at a cost exceeding £20,000 (US$26,500) per year, making it unaffordable for many.
Critics argue that these drugs, while a positive development, are costly to produce and come with potential side effects, including allergic reactions, brain swelling, and bleeding. Despite these concerns, the need for effective dementia treatments remains pressing, as the global societal costs of dementia were estimated at over US$1.3 trillion in 2019, and the number of new cases continues to rise, with someone being diagnosed every three seconds.
While these advancements do not offer a cure, they represent a hopeful step forward in managing a disease that affects millions worldwide. Ongoing research and development are crucial in the fight against dementia, as healthcare professionals and policymakers work to make these treatments more accessible and effective for those who need them most.
READ MORE: